Stock PPCB PROPANC BIOPHARMA, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Propanc Biopharma, Inc.

Equities

PPCB

US74346N6022

Pharmaceuticals

Market Closed - OTC Markets
Other stock markets
 20:59:43 10/05/2024 BST 		5-day change 1st Jan Change
0.001 USD 0.00% Intraday chart for Propanc Biopharma, Inc. +25.00% -91.67%
04-16 Propanc Biopharma, Inc. Receives Certificate of Grant for ?Composition of Proenzymes for Cancer Treatment? Patent from European Patent Office CI
04-16 Propanc Biopharma, Inc. announced that it has received $0.025 million in funding from GS Capital Partners LLC CI

Valuation

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Capitalization 1 - - 0.1833 0.641 0.5477 0.5585
Enterprise Value (EV) 1 - - 1.75 1.319 1.642 1.094
P/E ratio - - - - -0.07 x -0.08 x
Yield - - - - - -
Capitalization / Revenue - - - - - -
EV / Revenue - - - - - -
EV / EBITDA - - -0.5 x -0.73 x -0.83 x -0.62 x
EV / FCF - - -1.08 x -1.7 x -1.05 x -2.16 x
FCF Yield - - -92.3% -58.7% -95% -46.4%
Price to Book - - - -0.24 x -0.27 x -0.26 x
Nbr of stocks (in thousands) - - 0.05 12.4 149 4,137
Reference price 2 27,500,000 6,000,000 3,900 51.70 3.675 0.1350
Announcement Date 17/09/18 15/10/19 01/10/20 28/09/21 28/09/22 28/09/23
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Net sales - - - - - -
EBITDA 1 -3.958 -2.612 -3.492 -1.81 -1.989 -1.775
EBIT 1 -3.96 -2.615 -3.494 -1.812 -1.991 -1.777
Operating Margin - - - - - -
Earnings before Tax (EBT) 1 -7.218 -5.874 -4.875 -2.139 -2.713 -2.79
Net income 1 -7.039 -5.758 -4.741 -2.026 -2.658 -2.661
Net margin - - - - - -
EPS - - - - -49.23 -1.798
Free Cash Flow 1 -2.673 -1.243 -1.615 -0.7744 -1.559 -0.5074
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 17/09/18 15/10/19 01/10/20 28/09/21 28/09/22 28/09/23
1USD in Million
Estimates

Balance Sheet Analysis

Fiscal Period: Junio 2018 2019 2020 2021 2022 2023
Net Debt 1 4.73 1.74 1.57 0.68 1.09 0.54
Net Cash position 1 - - - - - -
Leverage (Debt/EBITDA) -1.196 x -0.6653 x -0.4487 x -0.3745 x -0.5502 x -0.3019 x
Free Cash Flow 1 -2.67 -1.24 -1.61 -0.77 -1.56 -0.51
ROE (net income / shareholders' equity) 115% 104% 119% 60.4% 87.3% 86.7%
ROA (Net income/ Total Assets) -2,974% -1,889% -2,182% -2,029% -2,626% -1,564%
Assets 1 0.2367 0.3049 0.2173 0.0998 0.1012 0.1701
Book Value Per Share - - - -219.0 -13.70 -0.5200
Cash Flow per Share - - - 0.1600 0.0200 0
Capex - 0 - - - -
Capex / Sales - - - - - -
Announcement Date 17/09/18 15/10/19 01/10/20 28/09/21 28/09/22 28/09/23
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Sector Other Pharmaceuticals

1st Jan change Capi.
PROPANC BIOPHARMA, INC. Stock Propanc Biopharma, Inc.
-91.67% 119K
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+30.38% 684B
NOVO NORDISK A/S Stock Novo Nordisk A/S
+26.51% 568B
JOHNSON & JOHNSON Stock Johnson & Johnson
-4.36% 361B
MERCK & CO., INC. Stock Merck & Co., Inc.
+19.30% 329B
ABBVIE INC. Stock AbbVie Inc.
+3.73% 284B
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.70% 240B
NOVARTIS AG Stock Novartis AG
+8.78% 208B
ROCHE HOLDING AG Stock Roche Holding AG
-7.93% 200B
AMGEN INC. Stock Amgen Inc.
+7.68% 166B
Other Pharmaceuticals
  1. Stock Market
  2. Equities
  3. PPCB Stock
  4. Financials Propanc Biopharma, Inc.